Siamab Therapeutics Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 9

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $202M

Siamab Therapeutics General Information

Description

Developer of a technology platform designed to develop therapies targeting cancers. The company's technology platform develops products based on new biological discoveries of non-human sialic acids, their dietary role and inflammatory consequences and their impact on cancer, cardiovascular and other inflammatory mediated diseases, enabling scientists in research of oncology, and antibody engineering to support anti-TACA antibody discovery and development programs.

Contact Information

Website
www.siamab.com
Formerly Known As
Sialix, Gc-Free
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • 90 Bridge Street
  • Suite 100
  • Newton, MA 02458
  • United States
+1 (800)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 90 Bridge Street
  • Suite 100
  • Newton, MA 02458
  • United States
+1 (800)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Siamab Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 19-Aug-2019 $202M Completed Out of Business
9. Angel (individual) 01-Apr-2019 Completed Generating Revenue
8. Later Stage VC 07-Nov-2018 Completed Generating Revenue
7. Later Stage VC (Series B) 29-Mar-2016 Completed Generating Revenue
6. Later Stage VC (Series B2) 23-Sep-2014 Completed Generating Revenue
5. Later Stage VC (Series B2) 10-Jul-2014 Completed Generating Revenue
4. Later Stage VC (Series B1) 10-Oct-2012 Completed Generating Revenue
3. Later Stage VC (Series B) 16-Aug-2011 Completed Generating Revenue
2. Early Stage VC (Series A) 19-Mar-2010 $700K $700K Completed Startup
1. Grant Completed Startup
To view Siamab Therapeutics’s complete valuation and funding history, request access »

Siamab Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A6
Series A5
Series A4
Series A3
Series A2 3,000,000 $0.001000 $0.02 $0.35 $0.35 1x $0.35 4.25%
Series A1 2,500,000 $0.001000 $0.02 $0.35 $0.35 1x $0.35 3.54%
To view Siamab Therapeutics’s complete cap table history, request access »

Siamab Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a technology platform designed to develop therapies targeting cancers. The company's technology platform de
Drug Discovery
Newton, MA
9 As of 2015

Niel, Belgium
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Siamab Therapeutics Competitors (101)

One of Siamab Therapeutics’s 101 competitors is etherna, a Formerly VC-backed company based in Niel, Belgium.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
etherna Formerly VC-backed Niel, Belgium
CytomX Therapeutics Formerly VC-backed South San Francisco, CA
TME Pharma Formerly VC-backed Berlin, Germany
Pure MHC Formerly VC-backed Austin, TX
Sorrento Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 101 competitors. Get the full list »

Siamab Therapeutics Patents

Siamab Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2018160909-A1 Glycan-interacting compounds and methods of use Inactive 03-Mar-2017
WO-2018094144-A1 Compositions and methods for treating cancer Inactive 17-Nov-2016
WO-2018094143-A1 Glycan-interacting compounds and methods of use Inactive 17-Nov-2016
WO-2017132486-A1 Compositions and methods for targeting cancer stem cells Inactive 27-Jan-2016
JP-2019500020-A Glycan interacting compounds and methods of use Active 12-Nov-2015 A61K47/6851
To view Siamab Therapeutics’s complete patent history, request access »

Siamab Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Siamab Therapeutics Former Investors (14)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bantam Group Angel Group Minority
Beacon Angels Angel Group Minority
Angel (individual) Minority
Boston Harbor Angels Angel Group Minority
Desert Angels Angel Group Minority
You’re viewing 5 of 14 investors. Get the full list »

Siamab Therapeutics FAQs

  • When was Siamab Therapeutics founded?

    Siamab Therapeutics was founded in 2006.

  • Where is Siamab Therapeutics headquartered?

    Siamab Therapeutics is headquartered in Newton, MA.

  • What is the size of Siamab Therapeutics?

    Siamab Therapeutics has 9 total employees.

  • What industry is Siamab Therapeutics in?

    Siamab Therapeutics’s primary industry is Drug Discovery.

  • Is Siamab Therapeutics a private or public company?

    Siamab Therapeutics is a Private company.

  • What is the current valuation of Siamab Therapeutics?

    The current valuation of Siamab Therapeutics is .

  • What is Siamab Therapeutics’s current revenue?

    The current revenue for Siamab Therapeutics is .

  • How much funding has Siamab Therapeutics raised over time?

    Siamab Therapeutics has raised $21.5M.

  • Who are Siamab Therapeutics’s investors?

    Bantam Group, Beacon Angels, , Boston Harbor Angels, and Desert Angels are 5 of 14 investors who have invested in Siamab Therapeutics.

  • Who are Siamab Therapeutics’s competitors?

    etherna, CytomX Therapeutics, TME Pharma, Pure MHC, and Sorrento Therapeutics are some of the 101 competitors of Siamab Therapeutics.

  • When was Siamab Therapeutics acquired?

    Siamab Therapeutics was acquired on 19-Aug-2019.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process